Filing Flows › Phathom Pharmaceuticals (PHAT) › Q2 2026 › vs Q2 2025
Phathom Pharmaceuticals (PHAT) Q2 2026 vs Q2 2025 (year over year)
Phathom Pharmaceuticals's revenue rose $34.8M (+88%) from $39.5M in Q2 2025 to $74.3M in Q2 2026.
Phathom Pharmaceuticals, Q2 2026: revenue $74.3M (+88% year over year), operating margin -5.3%, net loss $17.6M, operating cash flow −$1.9M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $74.3M | $39.5M | $34.8M | +88% |
| Net loss | $17.6M | $75.8M | −$58.2M | -77% |
| Costs & expenses | $91.9M | $115M | −$23.5M | -20% |
| Operating costs | $78.2M | $99.4M | −$21.2M | -21% |
| Interest & other, net | $13.6M | $15.9M | −$2.3M | -14% |
| Cost of revenue | $15.1M | $5.0M | $10.1M | +200% |
| Research & development | $7.8M | $9.1M | −$1.3M | -14% |
| SG&A | $55.3M | $85.3M | −$30.0M | -35% |
| Operating cash sources | $17.6M | $75.8M | −$58.2M | -77% |
| Depreciation & amortization | $114K | $172K | −$58K | -34% |
| Share-based compensation | $6.7M | $8.3M | −$1.6M | -19% |
| Working capital & other | $8.8M | $4.6M | $4.2M | +90% |
| Cash used in operations | $1.9M | $62.7M | −$60.8M | -97% |
| Net loss absorbed | $17.6M | $75.8M | −$58.2M | -77% |
Questions
How much did Phathom Pharmaceuticals's revenue grow year over year in Q2 2026?
Phathom Pharmaceuticals's revenue rose $34.8M (+88%) from $39.5M in Q2 2025 to $74.3M in Q2 2026.